The online version of this article (https://doi.org/10.1245/s10434-018-6705-1) contains supplementary material, which is available to authorized users.
The EUropean REgistration of Cancer CAre (EURECCA) consortium aims to investigate differences in treatment and to improve cancer care through Europe. The purpose of this study was to compare neo- and adjuvant chemotherapy (ACT) and outcome after tumor resection for pancreatic adenocarcinoma stage I and II in the EURECCA Pancreas consortium.
The eight, collaborating national, regional, and single-center partners shared their anonymized dataset. Patients diagnosed in 2012–2013 who underwent tumor resection for pancreatic adenocarcinoma stage I and II were investigated with respect to treatment and survival and compared using uni- and multivariable logistic and Cox regression analyses. All comparisons were performed separately per registry type: national, regional, and single-center registries.
In total, 2052 patients were included. Stage II was present in the majority of patients. The use of neo-ACT was limited in most registries (range 2.8–15.5%) and was only different between Belgium and The Netherlands after adjustment for potential confounders. The use of ACT was different between the registries (range 40.5–70.0%), even after adjustment for potential confounders. Ninety-day mortality was also different between the registries (range 0.9–13.6%). In multivariable analyses for overall survival, differences were observed between the national and regional registries. Furthermore, patients in ascending age groups and patients with stage II showed a significant worse overall survival.
This study provides a clear insight in clinical practice in the EURECCA Pancreas consortium. The differences observed in (neo-)ACT and outcome give us the chance to further investigate the best practices and improve outcome of pancreatic adenocarcinoma.
Supplementary material 1 (DOCX 17 kb)10434_2018_6705_MOESM1_ESM.docx
Supplementary material 2 (DOCX 19 kb)10434_2018_6705_MOESM2_ESM.docx
Supplementary Fig. S1 Flow chart of inclusion of patients per registry. aIncluded: C25.0-C25.9; excluded: C25.4.15 bIncludes only oncological resections. cUnable to confirm whether patients underwent tumor resection and therefore only used in patient and tumor characteristics description in Table S2 (Supplementary).d Included: 8140-8380, 8500-8585; excluded: 8150-8158, 8240-8249 15 (DOCX 331 kb)
Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(22):2140–1. PubMed
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86. CrossRef
L.H. Sobin MKG, Ch. Wittekind. TNM classification of malignant tumours, 7th edn. Geneva, Switzerland: International Union Against Cancer. 2009.
World-Health-Organization. International Classification of Diseases for Oncology (ICD-O-3) (3rd edn). 2013: http://codes.iarc.fr/. Accessed 18 Sept 2017.
Breugom AJ, Bastiaannet E, Boelens PG, et al. Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. Eur J Cancer. 2016;63:110–7. CrossRefPubMedPubMedCentral
Huang L, Jansen L, Balavarca Y, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. Nov 20 2017.
Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. Apr 30 2018.
Krautz C, Nimptsch U, Weber GF, Mansky T, Grutzmann R. Effect of hospital volume on in-hospital morbidity and mortality following pancreatic surgery in Germany. Ann Surg. Apr 04 2017.
- Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium
J. V. Groen
B. G. Sibinga Mulder
E. van Eycken
J. M. Borras
L. G. M. van der Geest
C. J. H. van de Velde
B. A. Bonsing
J. S. D. Mieog
- Springer International Publishing
Neu im Fachgebiet Chirurgie
e.Med Kampagnen-Visual, Mail Icon II